Decreased carriage and genetic shifts in the streptococcus pneumoniae population after changing the seven-valent to the thirteen-valent pneumococcal vaccine in Norway

Pediatric Infectious Disease Journal

Volumn 34, Issue 8, 2015, Pages 875-883

  Steens, Anneke ^a   Caugant, Dominique A ^a,b   Aaberge, Ingeborg S ^a   Vestrheim, Didrik F ^a,c  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

antibiotic resistance; multilocus sequence typing; pneumococcal carriage; pneumococcal conjugate vaccine; serotype diversity; Streptococcus pneumoniae

Indexed keywords

CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; PENICILLIN G; PNEUMOCOCCUS VACCINE; TETRACYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; AUTUMN; BACTERIUM CARRIER; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BREAST FEEDING; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAY CARE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MICROBIAL POPULATION DYNAMICS; MULTILOCUS SEQUENCE TYPING; NONHUMAN; NOSE SMEAR; PASSIVE SMOKING; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SEROTYPE; SEROTYPING; SIBLING; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFANT; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NORWAY; PNEUMOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; NORWAY; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE;

EID: 84937422392     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000751     Document Type: Article

References (48)

1. Bogaert D, Keijser B, Huse S, et al. Variability and diversity of nasopharyngeal microbiota in children: a metagenomic analysis. PLoS One. 2011; 6: e17035
2. Melegaro A, Gay NJ, Medley GF. Estimating the transmission parameters of pneumococcal carriage in households. Epidemiol Infect. 2004; 132: 433-441
3. Spijkerman J, Van Gils EJ, Veenhoven RH, et al. Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerg Infect Dis. 2011; 17: 584-591
4. Melegaro A, Choi Y, Pebody R, et al. Pneumococcal carriage in United Kingdom families: estimating serotype-specific transmission parameters from longitudinal data. Am J Epidemiol. 2007; 166: 228-235
5. Lipsitch M, Abdullahi O, D'Amour A, et al. Estimating rates of carriage acquisition and clearance and competitive ability for pneumococcal serotypes in Kenya with a Markov transition model. Epidemiology. 2012; 23: 510-519
6. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004; 4: 144-154
7. Pavia M, Bianco A, Nobile CG, et al. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-Analysis. Pediatrics. 2009; 123: e1103-e1110
8. Lucero MG, Dulalia VE, Parreno RN, et al. Pneumococcal conjugate vaccines for preventing vaccine-Type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. Cochrane Database Syst Rev.2004: CD004977
9. Brueggemann AB, Pai R, Crook DW, et al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog. 2007; 3: e168
10. Nurhonen M, Auranen K. Optimal serotype compositions for Pneumococcal conjugate vaccination under serotype replacement. PLoS Comput Biol. 2014; 10: e1003477
11. Van Hoek AJ, Sheppard CL, Andrews NJ, et al. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine. 2014; 32: 4349-4355
12. Yildirim I, Hanage WP, Lipsitch M, et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine. 2010; 29: 283-288
13. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011; 11: 760-768
14. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease following pneumococcal vaccination: a discussion of the evidence. Lancet.2011; 378: 1962-1973
15. Hicks LA, Harrison LH, Flannery B, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007; 196: 1346-1354
16. Vestrheim DF, Høiby EA, Bergsaker MR, et al. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine. 2010; 28: 2214-2221
17. Lexau CA, Lynfield R, Danila R, et al; Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005; 294: 2043-2051
18. Hanage WP, Finkelstein JA, Huang SS, et al. Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics. 2010; 2: 80-84
19. Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013; 31: 6232-6238
20. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013; 32: 203-207
21. Guevara M, Ezpeleta C, Gil-Setas A, et al; Working Group for Surveillance of the Pneumococcal Disease in Navarre. Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001-2013. Vaccine. 2014; 32: 2553-2562
22. Moore CE, Paul J, Foster D et al. Reduction of invasive pneumococcal disease three years after the introduction of the 13 valent conjugate vaccine in the Oxfordshire region, England. J Infect Dis.2014
23. Vestrheim DF, Høiby EA, Aaberge IS, et al. Phenotypic and genotypic characterization of Streptococcus pneumoniae strains colonizing children attending day-care centers in Norway. J Clin Microbiol. 2008; 46: 2508-2518
24. Vestrheim DF, Høiby EA, Aaberge IS, et al. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol. 2010; 17: 325-334
25. Child-care, 2010. [Statistics Norway Web Site]. Available at: http://www.ssb.no/en/utdanning/statistikker/kontantstotte/hvert-2-Aar. Accessed May 2, 2011
26. Riise O. Delay in the Norwegian Immunisation Programme [abstract]. Philadelphia: IDWEEK; 2014, Abstract number 1066
27. Clinical Breakpoints. [European Committee on Antimicrobial Susceptibility Testing (EUCAST) Web Site]. Available at: http://www.eucast.org/clinical- breakpoints/. Accessed November 20, 2013
28. Enright MC, Spratt BG. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology. 1998; 144: 3049-3060
29. Simpson EH. Measurement of diversity. Nature.1949; 163: 688
30. Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis. 2013; 57: 952-962
31. Lee GM, Kleinman K, Pelton SI, et al. Impact of 13-valent pneumococcal conjugate vaccination on streptococcus pneumoniae carriage in young children in Massachusetts. J Pediatric Infect Dis Soc. 2014; 3: 23-32
32. Gounder PP, Bruce MG, Bruden DJ, et al. Effect of the 13-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae-Alaska, 2008-2012. J Infect Dis. 2014; 209: 1251-1258
33. Ricketson LJ, Wood ML, Vanderkooi OG, et al; Calgary Streptococcus pneumoniae Epidemiology Research (CASPER) investigators. Trends in asymptomatic nasopharyngeal colonization with streptococcus pneumoniae after introduction of the 13-valent pneumococcal conjugate vaccine in Calgary, Canada. Pediatr Infect Dis J. 2014; 33: 724-730
34. Leino T, Hoti F, Syrjänen R, et al. Clustering of serotypes in a longitudinal study of Streptococcus pneumoniae carriage in three day care centres. BMC Infect Dis. 2008; 8: 173
35. Sá-Leão R, Nunes S, Brito-Avô A, et al. High rates of transmission of and colonization by Streptococcus pneumoniae and Haemophilus influenzae within a day care center revealed in a longitudinal study. J Clin Microbiol. 2008; 46: 225-234
36. Sleeman KL, Griffiths D, Shackley F, et al. Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis. 2006; 194: 682-688
37. Hammitt LL, Bruden DL, Butler JC, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis. 2006; 193: 1487-1494
38. Loughlin AM, Hsu K, Silverio AL, et al. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts' children. Pediatr Infect Dis J. 2014; 33: 504-510
39. Scott JR, Hanage WP, Lipsitch M, et al. Pneumococcal sequence type replacement among American Indian children: a comparison of pre- and routine-PCV7 eras. Vaccine. 2012; 30: 2376-2381
40. Hanage WP, Huang SS, Lipsitch M, et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis. 2007; 195: 347-352
41. Vestrheim DF, Steinbakk M, Aaberge IS, et al. Postvaccination increase in serotype 19A pneumococcal disease in Norway is driven by expansion of penicillin-susceptible strains of the ST199 complex. Clin Vaccine Immunol. 2012; 19: 443-445
42. Kim DS, Shin SH, Lee HJ, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to Korean children receiving routine pediatric vaccines. Pediatr Infect Dis J. 2013; 32: 266-273
43. Weckx LY, Thompson A, Berezin EN, et al; 012 Study Group. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine. 2012; 30: 7566-7572
44. Kieninger DM, Kueper K, Steul K, et al; 006 study group. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010; 28: 4192-4203
45. Scott DA, Komjathy SF, Hu BT, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2007; 25: 6164-6166
46. Nunes MC, Madhi SA. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vaccines. 2011; 10: 951-980
47. Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011; 29: 9127-9131
48. Statistics from the Norwegian Prescription Database. [Norwegian Institute for Public Health Web Site]. Available at: http://www.norpd.no/Prevalens. aspx. Accessed July 8, 2014